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Potential Mediators between Fibromyalgia
and C-Reactive protein: Results from a
Large U.S. Community Survey
Termeh Feinberg1,2* , Usha Sambamoorthi3, Christa Lilly4 and Kim Karen Innes2,5

Abstract
Background: Fibromyalgia, a potentially debilitating chronic pain syndrome of unknown etiology, may be characterized
by inflammation. In this study, we investigated the relation of FMS to serum C-reactive protein (CRP) in a large population
of adults (18+) and investigated the influence of other factors on this relationship, including BMI, comorbidities, as well as
mood and sleep disturbance.
Methods: Participants were 52,535 Ohio Valley residents (Fibromyalgia n = 1125). All participants completed a
comprehensive health survey (2005–2006) part of the C8 Health Project; serum levels of CRP were obtained, as was
history of Fibromyalgia physician diagnosis. Logistic and linear regressions were used for this cross-sectional analysis.
Results: Mean CRP was higher among participants reporting Fibromyalgia than those without (5.54 ± 9.8 vs.3.75 ± 7.
2 mg/L, p < .0001)). CRP level showed a strong, positive association with FMS (unadjusted odds ratio (OR) for highest
vs. lowest quartile = 2.5 (CI 2.1,3.0;p for trend < .0001)); adjustment for demographic and lifestyle factors attenuated but
did not eliminate this association (AOR for highest vs. lowest quartile = 1.4 (CI 1.1,1.6;p for trend < .0001)). Further addition
of body mass index (BMI) and comorbidities to the model markedly weakened this relationship (AORs, respectively, for
highest vs lowest CRP quartile = 1.2 (CI 1.0,1.4) and 1.1 (CI 0.9,1.3). In contrast, inclusion of mood and sleep impairment
only modestly reduced the adjusted risk estimate (AORs for highest vs. lowest quartile = 1.3 (CI 1.1,1.5) for each)).
Conclusions: Findings from this large cross-sectional study indicate a significant positive cross-sectional association of
Fibromyalgia to serum C-reactive protein may be explained, in part, by BMI and comorbidity. Prospective research is
needed to confirm this, and clarify the potential mediating influence of obesity and comorbid conditions on this
relationship.
Keywords: Fibromyalgia, C-reactive protein, Inflammation, Body mass index, Comorbidity, Mediator, Epidemiology

Background
Chronic pain, defined as ongoing or recurrent pain that extends beyond the usual course of acute illness or injury for
at least three to six months, is debilitating and costly. Over
20% of adults experience chronic pain at some point in
their lives [1]. Fibromyalgia syndrome (FMS) is a rheumatologic chronic pain syndrome affecting approximately
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0.5–5% of populations in developed countries [2], including 1.75% of those in the U.S. [3]. FMS is characterized by
a constellation of somatic symptoms that are typically
present in addition to widespread pain (e.g., fatigue, sleep
disturbance, memory, and mood problems), for which no
clear cause can be found [4]. FMS is typically accompanied
by morning stiffness, and sensitivity to loud noises, bright
lights, and temperature extremes; women with FMS often
report painful menstrual periods [5]. Although FMS affects
both sexes and people of all ages, the majority (80–90%)
have been Caucasian [5, 6] middle-aged women [5]. Family
members of FMS patients are at a higher risk for FMS [7];
the cause is unknown.
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While the etiology of FMS remains poorly understood, the widespread pain of FMS is thought to reflect
abnormal central nervous system sensory information
processing, with altered function in pain pathways and
neuroendocrine disturbance [4]; Inflammatory processes may also play a significant role in the pathogenesis of FMS [8]. Although several MicroRNAs have
been associated with FMS and symptom severity [9],
diagnosis of FMS remains challenging, and there are
currently no definitive diagnostic laboratory tests for
the disease [10].
C-reactive protein (CRP), previously considered a biomarker of underlying infection or tissue injury [11], is
now also believed to reflect chronic systemic inflammation [12]. CRP is considered a reliable proinflammatory
biomarker [11] and is often included as part of the diagnostic laboratory workup for many rheumatological conditions [11]. While CRP is often included in the
diagnostic workup for FMS, the relationship of CRP to
FMS has not been clearly established.
Inflammation, as a characteristic reaction of tissues to
injury or disease marked by physical swelling, redness,
heat, and pain upon clinical examination, is not a classical symptom of FMS [10]. Inflammatory cytokines
promote the development of contralateral hyperalgesia
(an extreme, exaggerated reaction to pain) and allodynia (central pain sensitization following painful, often
repetitive stimulation) [13]. FMS is typically characterized by both [14], and most [15–28], but not all recent
studies [23, 29] have suggested a possible link between
systemic inflammation and FMS. Of these, five studies
measured CRP [24, 26–28, 30]; four suggested a positive association between CRP and FMS [24, 26–28].
However, to date, only one large, cross-sectional,
population-based study has examined the association of
CRP to FMS [27]. The study excluded women, and
combined FMS with other pain syndromes, rendering
assessment of the specific relationship between CRP
and FMS difficult.
Moreover, to our knowledge, no studies to date examining the association of CRP to FMS have investigated
the potential mediating effects of sleep or mood disturbance, factors linked to both elevated CRP levels and
FMS [31–34]. Few have assessed the influence of elevated BMI [33, 35], comorbidities, and other correlates
[24]. This large, population-based study will fill the gaps
in our understanding of the potential influence(s) of
mood, sleep, BMI, and comorbid conditions on the relationship between CRP and FMS.

Methods
In this study, we investigated the relation of serum CRP
levels to FMS in a large population of US adults.
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Data source

This cross-sectional study used data from the C8 Health
Project, which was conducted as part of the settlement
of a class-action lawsuit stemming from drinking water
contamination by Perfluorooctanoic Acid (PFOA) released from the DuPont Washington Works Plant near
Parkersburg, WV, USA [36]. Data collection was conducted in 2005–2006 on individuals living or working in
6 PFOA-contaminated public water districts in West
Virginia (WV) and Ohio (including those exposed to
contaminated private-well drinking water) since 1951; a
total of 69,030 individuals participated in the study, including 81% of eligible adults [36]. Project data collection was administered by an independent company,
Brookmar, Inc. (Parkersburg, WV), and was conducted
under the authority and supervision of the Wood
County, WV, Circuit Court. Participants completed a
comprehensive health questionnaire and volunteered a
blood sample after completing individual consent forms
for both. Demographic data and health survey completion were verified by trained project staff [36]. Project
procedures, blood processing and assay methods, along
with quality-assurance measures, have been described in
detail elsewhere [36]. Briefly, following collection of each
blood sample, serum was separated from red blood cells
into single-use aliquots by centrifusion, and was refrigerated at individual data collection sites until daily pickup
from a large, independent, accredited clinical diagnostic
laboratory (LabCorp, Inc., Burlington, NC, USA). Samples were transported to a regional processing center
(LabCorp, Inc., Columbus, OH) where they underwent
analysis by latex immunoturbidimetry on a COBAS Integra 800 (Roche, Germany). The West Virginia University
(WVU) IRB permitted access to the de-identified data by
WVU investigators. Demographic, lifestyle, and health
characteristics were determined via self-report; diagnoses
of certain disorders, including diabetes and cardiovascular diseases, were further verified via chart review.

Study population

Our analysis excluded participants who were missing
data on age or <18 years of age (n = 12,471, 18.1%),
pregnant (n = 640, 1.1%); those reporting a cancer diagnosis and receiving treatment for diagnosed cancer other
than non-melanoma skin cancer (n = 437, 0.77%) to
eliminate potential bias introduced by varied CRP levels
as a result of chemotherapy treatment; those with
service-related disabilities (n = 710, 1.3%); and those
who did not complete both the survey and blood work
(n = 468, 0.83%). Participants with extreme body mass
index (BMI) values (<10.5 and >60.0) were also excluded
to eliminate potential information bias (n = 94, 0.17%).
Further exclusion of persons with missing data on CRP
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and FMS (n = 40, 0.002%) and other covariates of interest (n = 1673, 3.1%), with the exception of covariates for
which missing data on >10% of participants occurred
(for which a ‘missing’ category was included in analysis),
yielded a final study sample of 52,535, including 51,410
FMS-free controls and 1125 adults with FMS (Fig. 1).
Outcome variable

Our primary, dichotomous outcome variable was FMS
diagnosis, which was ascertained via self-report response
to the question “Have you ever been diagnosed with
Fibromyalgia?”
Exposure variable

Our primary exposure variable was serum level of inflammatory marker CRP (mg/L). The normal CRP range
in the general population is considered 0.0–5.0 mg/L
[28]. Further, in healthy young adult volunteer blood donors, the median concentration of CRP is 0.8 mg/L, the
90th centile is 3.0 mg/L, and the 99th centile is 10 mg/L;
following an acute-phase stimulus, values may increase
from less than 50 μg/L to more than 500 mg/L [11]. C8
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Health Project coordinators recoded CRP values below
the level of detection to 50% of the lowest level (i.e.,
“<0.3” → 0.15). Likewise, values above the level of detection were recoded to 50% above the maximum level.
Covariates

In addition to age, gender, race, education, employment,
marital status, income, alcohol or tobacco use, and exercise program status, comorbid conditions were also selected a priori as covariates if known or suspected to be
associated with FMS and/or CRP. These included BMI
[37], autoimmune conditions [38], osteoarthritis [39],
kidney [40], respiratory [41], cardiovascular [40], liver
[42], and endocrine [40] disease, diabetes [43], severe allergies [40] and sinus disease [44], stomach conditions
[40, 42], and headache [45]. PFOA serum level and reproductive factors [46] were also examined as covariates.
Potential mediating and modifying factors

Potential mediating and modifying factors included fatigue,
sleep impairment [42], mood disturbance [32, 40, 42], age
[5], gender [5], obesity [35], tobacco use [47], statin use
[48], and reproductive factors [46].
Statistical analysis

Fig. 1 a: with exceptions of income and current menstruation,
which contained ≥10% of missing values; these were considered
separate categories for analysis

We conducted complete-case analyses using SAS 9.4
(Cary, NC, USA). Logistic regression analyses were used
to evaluate the independent association of CRP level to
FMS status, and to assess the influence of potential confounding, mediating, and modifying factors. The primary
explanatory variable of interest, CRP, was analyzed as a
continuous and categorical variable (study population
quartiles, with the lowest percentile group used as the
referent). Linear trends for CRP quartiles were assessed
using polynomial contrasts. Differences between participants missing any data were assessed using logistic regression. Cox-Snell R2 values measured the predictive
power of models. All p-values shown are two-sided.
All demographic characteristics, in addition to lifestyle
factors significantly differing by FMS, were controlled
for in multivariate models. BMI was categorized using
the National Institutes of Health clinical classifications
(scores of <25 = ‘Underweight or Normal weight’; 25–
29.9 = ‘Overweight’; 30–34.9 = ‘Obese Class 1’; and,
35 + =‘Obese Classes 2/3’) [49].
We evaluated the influence of both specific comorbid
conditions and total number of comorbid conditions on
the relation of CRP to FMS. A comorbidity index was created based on number of chronic comorbid conditions reported; these included: autoimmune disorders (defined as
having any diagnoses of immune disease, lupus, or
rheumatoid arthritis), osteoarthritis, allergies or frequent
sinusitis, kidney disease, respiratory conditions (asthma,
emphysema, chronic obstructive pulmonary disorder,
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bronchitis), heart disease, liver disease, endocrine disorders (thyroid, Addison’s, or Cushing’s disease), diabetes, or
frequent headaches. This index was evaluated as both a
continuous and categorical variable (‘none’, ‘1 comorbidity’,
2 comorbidities’, and ‘3+ comorbidities’).
We assessed potential mediating influences of sleep
impairment and mood disturbance. A composite sleep
quality variable, with higher scores indicating poorer
sleep quality, was derived from responses to individual
questions regarding the frequency of short sleep, fitful
sleep, insomnia, and/or daytime somnolence (scored as
follows: 3 = ‘frequently’, 2 = ‘sometimes’, 1 = ‘rarely’, and
0 = ‘never’, for each). Mood disturbance was also
assessed as a composite variable from responses to four
individual questions, with higher scores indicating frequent mood swings, irritability, fatigue, and/or inability
to concentrate (where 3 = ‘frequently’, 2 = ‘sometimes’,
1 = ‘rarely’, and 0 = ‘never’).
Additionally, we assessed the potential modifying influence of age (<45 vs. ≥45 years), tobacco use (‘current’/
‘not currently using tobacco’), gender, obesity (BMI < 30
vs. ≥30) current menstruation (yes/no), menopausal status (peri- or post-menopausal/premenopausal), statin
use (yes/no), and sleep impairment and mood disturbance (scores of <6 vs. ≥ 6, respectively) on the association between CRP and FMS.
We also conducted separate ancillary analyses adjusting for statin use (yes/no), PFOA serum level (ng/mL,
evaluated as quartiles), and reproductive characteristics
(women only) to determine the potential confounding
influence of these factors on any observed association
between CRP and FMS. Reproductive factors assessed
included menopausal status (‘pre-menopausal’; ‘peri-or
post-menopausal’; or ‘unsure’), parity (number of pregnancies), and age at menarche (‘16+ years of age’/‘other
age or unsure’).
The first regression model assessed the crude association of CRP levels to reported FMS diagnosis. The second model was adjusted for demographic and lifestyle
covariates, while additional models adjusted for BMI
and comorbid conditions, as well as sleep and mood
disturbance (separately and combined, respectively).
We conducted additional analyses to evaluate the potential confounding influence of statin use, PFOA
serum level, and (in female participants) reproductive
history (i.e., menopausal status, age at menarche, and
parity).
The potential mediating effects of BMI and comorbid
conditions, as well as sleep impairment and mood disturbance were examined using separate logistic regression
models. We also conducted ancillary analyses excluding
autoimmune disorders rheumatoid arthritis, lupus, and
self-reported ‘previous diagnosis of immune disorder.’ To
evaluate the potential modifying effects of age, smoking,
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gender, obesity, current menstruation, menopausal status,
statin use, sleep impairment, and mood disturbance, we
conducted multivariable analyses; interactions were
assessed by including the corresponding multiplicativeinteraction term in the statistical models.

Results
Relative to participants with complete data, those with
missing data on key covariates had a higher number of
comorbidities and were more likely to be poorly educated or to be retired, disabled, or unemployed
(p’s ≤ .002), but did not differ in other factors. Demographic and lifestyle characteristics are displayed in
Table 1. Study participants were predominantly white
(97.2%), female (52.4%), and married or cohabitating
(68.9%). Participant age ranged from 18.0 to 105.2 years,
averaging 45.3 (SD = 16.1) years. Most participants were
employed or students (64.1%) and overweight (69.0%
BMI ≥ 25, mean BMI = 28.5, SD = 6.3), while nearly half
did not currently consume alcohol (51.1%) and never
smoked (43.5%). CRP serum levels varied from 0.15 to
250.6 (mean CRP level = 3.79, SD = 7.2) mg/L. Additionally, PFOA was not significantly associated with
CRP after adjustment with all factors used in other
models (p = .084).
FMS was present in 2.1% of the study population
(n = 1125). After adjustment for demographic and lifestyle factors, the odds of FMS increased 2% for every
year-unit increase in age (Adjusted odds ratio
(AOR) = 1.02, 95% confidence interval (CI): 1.02, 1.03
(Table 1)), with a significantly higher mean age among
FMS cases (M = 51.1, SD = 11.6) compared to controls
(M = 45.1, SD = 16.2). Those aged 45–64 years were 8.3
times more likely (AOR = 8.28, CI 4.91, 13.95) than
those in the age group 18–24 years to have FMS. Those
with FMS were nearly 11 times more likely to be female
(AOR = 10.68, CI 8.53, 13.37). Participants who were
employed or students were less likely to have FMS than
all others, as were those with <12th grade education,
compared to those with higher educational attainment.
Relative to participants who were married or cohabitating, those who were single were almost 40% less likely to
report a diagnosis of FMS (AOR = 0.63, CI 0.47, 0.84).
Participants who reported current consumption of alcohol
were slightly less likely to report a diagnosis of FMS
(35.8% vs. 49.2%, respectively; AOR = 0.86, CI 0.75, 0.98),
and women who had experienced menopause were about
80% more likely to have an FMS diagnosis compared to
pre-menopausal women (AOR = 1.82, CI 1.49, 2.21).
Health characteristics of the study population are detailed in Table 2. Mean BMI was significantly higher
among FMS cases (M = 30.47, SD = 7.2) than controls
(M = 28.49, SD = 6.3), and was significantly and positively associated with FMS after adjustment for
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Table 1 Characteristics of a US adult population by Fibromyalgia (FMS) status, Adjusted for Demographic and Lifestyle factors, C8
Health Project, 2005–2006
FMS

Non-FMS

Adjusted Odds Ratioa

52,535

1125 (2.1%)

51,410 (97.9%)

−

45.25 (16.14)

51.14 (11.58)

45.12 (16.20)

1.02 (1.02–1.03), <.0001*

18–24 (ref)

6540 (12.5%)

16 (1.4%)

6524 (12.7%)

−

25–44

20,178 (38.4%)

300 (26.7%)

19,879 (38.7%)

3.89 (2.30–6.56), <.0001*

45–64

19,098 (36.4%)

689 (61.2%)

18,409 (35.8%)

8.28 (4.91–13.95), <.0001*

65+

6719 (12.8%)

120 (10.7%)

6599 (12.8%)

4.37 (2.50–7.64), <.0001*

Characteristic

Total Population

Total
Age (years)

N (%) / Mean (SD)

OR (CI), p-value

Age

Gender
Male (ref)
Female

25,002 (47.6%)
27,533 (52.4%)

90 (8.0%)

24,912 (48.5%)

−

1035 (92.0%)

26,498 (51.5%)

10.68 (8.53–13.37), <.0001*

Race/Ethnicity
Non-Hispanic White

51,092 (97.2%)

1098 (97.6%)

49,994 (97.2%)

1.09 (0.73–1.62), .683

Other Race (ref)

1443 (2.8%)

27 (2.4%)

1416 (2.8%)

−

< 12th grade (ref)

6261 (11.9%)

106 (9.4%)

6155 (12.0%)

−

HS/GED

22,353 (42.6%)

445 (39.6%)

21,908 (42.6%)

1.57 (1.25–1.96), .0001*

Some College

17,081 (32.5%)

442 (39.3%)

16,639 (32.4%)

2.22 (1.75–2.82), <.0001*

Bachelor’s degree+

6840 (13.0%)

132 (11.7%)

6708 (13.1%)

1.91 (1.42–2.56), <.0001*

Employed/Student (ref)

33,682 (64.1%)

482 (42.8%)

33,200 (64.6%)

−

Retired/Unemployed

9057 (17.2%)

144 (12.8%)

8913 (17.3%)

1.44 (1.16–1.79), .0008*

Disabled

3357 (6.4%)

252 (22.4)

3105 (6.0%)

5.70 (4.73–6.87), <.0001*

Homemaker

5979 (11.4%)

233 (20.7%)

5746 (11.2%)

1.50 (1.26–1.78), <.0001*

Other

460 (0.88%)

14 (1.2%)

446 (0.9%)

2.23 (1.28–3.88), .004*

Married/Cohabitating (ref)

36,198 (68.9%)

836 (74.3%)

35,362 (68.8%)

−

Single

8729 (16.6%)

60 (5.3%)

8669 (16.9%)

0.63 (0.47–0.84), .002*

Divorced/Sep/Widow

7608 (14.5%)

229 (20.4%)

7379 (14.4%)

0.85 (0.71–1.01), .058

5335 (10.2%)

92 (8.2%)

5243 (10.2%)

0.85 (0.66–1.10), .217

Education

Employment

Marital Status

Household Income
Don’t know/Missing
< $20,000 (ref)

12,308 (23.4%)

288 (25.6%)

12,020 (23.4%)

−

$20,000–40,000

14,326 (27.3%)

301 (26.8%)

14,025 (27.3%)

1.03 (0.86–1.24), .759

$40,001–70,000

13,559 (25.8%)

291 (25.9%)

13,268 (25.8%)

1.05 (0.86–1.29), .619

7007 (13.3%)

153 (13.6%)

6854 (13.3%)

1.09 (0.85–1.39), .514

Don’t drink (ref)

26,847 (51.1%)

722 (64.2%)

26,125 (50.8%)

−

Currently Drink

25,688 (48.9%)

403 (35.8%)

25,285 (49.2%)

0.86 (0.75–0.98), .023*

$70,000+
Alcohol

Tobacco User
Never (ref)

22,859(43.5%)

567 (50.4%)

22,292 (43.4%)

−

Current

16,691 (31.8%)

274 (24.4%)

16,417 (31.9%)

0.91 (0.78–1.07), .243
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Table 1 Characteristics of a US adult population by Fibromyalgia (FMS) status, Adjusted for Demographic and Lifestyle factors, C8
Health Project, 2005–2006 (Continued)
Former

12,985 (24.7%)

284 (25.2%)

12,701 (24.7%)

1.06 (0.91–1.23), .441

No regularity (ref)

36,113 (68.7%)

762 (67.7%)

35,351 (68.8%)

−

Regular exercise

16,422 (31.3%)

363 (32.3%)

16,059 (31.2%)

−

Menopause occurred

10,526 (38.2%)

631 (61.0%)

9895 (37.3%)

1.82 (1.49, 2.21), <.0001*

Exercise Program

Note: Column Percentages shown
*Significant at p < 0.05
a
Model adjusted for demographic covariates Age, Gender, Marital Status, Employment, Education level, White Race, and Household Income; Also adjusted for
lifestyle covariates Tobacco Use and Current Alcohol consumption

demographic and lifestyle factors (AOR per unit BMI increase = 1.02, CI 1.01, 1.03). Relative to those with a
BMI <25, participants who were obese were significantly
more likely to have FMS (AOR = 1.24, CI 1.02, 1.49;

and, AOR = 1.43, CI 1.18, 1.74, for BMI 30–35 and BMI
>35, respectively). There was a 60% increase in FMS
diagnosis for each additional comorbidity (AOR = 1.60,
CI 1.54, 1.67 (Table 2); participants reporting a diagnosis

Table 2 Health Characteristics of a US adult population by Fibromyalgia (FMS) status, Adjusted for Demographic and Lifestyle
factors, C8 Health Project, 2005–2006
FMS

Non-FMS

Adjusted Odds Ratioa

28.53 (6.31)

30.47 (7.22)

28.49 (6.28)

1.02 (1.01–1.03), .001*

≤ 24.99 (ref)

16,258 (31.0%)

279 (24.8%)

15,979 (31.1%)

−

25.5–29.99

18,200 (34.6%)

320 (28.4%)

17,880 (34.8%)

1.11 (.932–1.31), .248

30–34.9

10,704 (20.4%)

251 (22.3%)

10,453 (20.3%)

1.24 (1.02–1.49), .028*

35+

7373 (14.0%)

275 (24.4%)

7098 (13.8%)

1.43 (1.18–1.74), .0003*

1.29 (1.27)

2.78 (1.59)

1.25 (1.24)

1.60 (1.54–1.67), <.0001*

Characteristic

Total Population

BMI+

N (%) / Mean (SD)

Number of Comorbidities

OR (CI), p-value

Comorbidity Index
None (ref)

16,778 (31.9%)

58 (5.2%)

16,720 (32.5%)

−

1

16,999 (32.4%)

177 (15.7%)

16,822 (32.7%)

2.38 (1.77–3.21), <.0001*

2

10,535 (20.1%)

301 (26.8%)

10,234 (19.9%)

5.16 (3.88–6.86), <.0001*

3+

8223 (15.7%)

589 (52.4%)

7634 (14.9%)

10.46 (7.90–13.84), <.0001*

Autoimmune disorder

2192 (4.2%)

220 (19.6%)

1972 (3.8%)

3.43 (2.89–4.06), <.0001*

Osteoarthritis

4093 (7.7%)

411 (35.5%)

3782 (7.1%)

3.86 (3.34–4.45), <.0001*

Allergies or Chronic Sinusitis

24,470 (46.6%)

893 (79.4%)

23,577 (45.9%)

2.91 (2.51–3.38), <.0001*

Kidney disorder

5202 (9.9%)

226 (20.1%)

4976 (9.7%)

1.72 (1.47–2.01), <.0001*

Respiratory disease

7385 (14.1%)

342 (30.4%)

7043 (13.7%)

1.89 (1.64–2.17), <.0001*

Cardiovascular disease

4661 (8.9%)

148 (13.2%)

4513 (8.9%)

1.25 (1.03–1.51), .027*

Liver disease

684 (1.3%)

38 (3.4%)

646 (1.3%)

1.51 (1.06–2.16), .022*

Endocrine Disorder

4083 (7.8%)

264 (23.5%)

3819 (7.4%)

1.82 (1.57–2.12), <.0001*

Diabetes

4778 (9.1%)

157 (14.0%)

4621 (9.0%)

.978 (.813–1.18), .810

Frequent Headache

10,105 (19.2%)

439 (39.0%)

9666 (18.8%)

2.03 (1.78–2.31), <.0001*

4.00 (3.56)

7.32 (3.29)

3.93 (3.53)

1.23 (1.21–1.25), <.0001*

4.59 (3.70)

7.25 (3.40)

4.53 (3.68)

1.19 (1.17–1.21), <.0001*

Sleep Impairment Scoreb
m

Mood Disturbance Score

Note: Column Percentages shown
*Significant at p < 0.05
a
Model adjusted for demographic covariates Age, Gender, Marital Status, Employment, Education level, White Race, and Household Income; Also adjusted for
lifestyle covariates Tobacco Use and Current Alcohol consumption
b
Sleep impairment derived from responses to four individual questions regarding the frequency of short sleep, fitful sleep, insomnia and/or daytime somnolence;
higher score indicates increased frequency of impairment
m
Mood disturbance derived from responses to four individual questions regarding frequent mood swings, irritability, fatigue and/or inability to concentrate;
higher score indicates increased frequency of disturbance
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of 3 or more comorbidities were 10.5 times more likely
to have FMS (AOR = 10.46, CI 7.90, 13.84) compared to
those with no comorbidities. FMS was likewise strongly
and positively associated with most chronic conditions
evaluated, including in order of decreasing magnitude
osteoarthritis (AOR = 3.86, CI 3.34, 4.45), autoimmune
disease (AOR = 3.43, CI 2.89, 4.06), allergies/chronic sinusitis (AOR = 2.91, CI 2.51, 3.38), frequent headaches
(AOR = 2.03, CI 1.78, 2.31), and kidney (AOR = 1.72, CI
1.47, 2.01), respiratory (AOR = 1.89, CI 1.64, 2.17),
endocrine (AOR = 1.82, CI 1.57, 2.12), and liver
(AOR = 1.51, CI 1.06, 2.16) diseases.
FMS cases reported higher sleep (M = 7.3, SD = 3.3 vs.
M = 3.9, SD = 3.5) and mood disturbance scores (M = 7.3,
SD = 3.4 vs. M = 4.5, SD = 3.7) than did controls (Table
2). After adjustment for demographic and lifestyle factors,
FMS remained strongly and positively related to scores for
both sleep (AOR = 1.23, CI 1.21, 1.25), and mood disturbance (AOR = 1.19, CI 1.17, 1.21).
Relation of CRP to FMS

Mean CRP (mg/L) was significantly higher among FMS
cases (M = 5.54, SD = 9.8) compared to controls
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(M = 3.75, SD = 7.2) (Table 3). CRP serum level showed
a positive association with FMS (unadjusted OR for
highest vs. lowest quartile = 2.50, CI 2.10, 2.97; P for
trend <.0001); adjustment for demographic and lifestyle
factors substantially attenuated but did not eliminate this
association (AOR for highest vs. lowest quartile = 1.35,
CI 1.13, 1.62; P for trend <.0001). Analysis of CRP as a
continuous variable yielded similar findings, with odds
of FMS increasing by 2% for each one mg/L of CRP rise
(unadjusted OR = 1.02, CI 1.01, 1.02); adjustment for
demographic and lifestyle factors slightly attenuated this
association (AOR = 1.01, CI 1.00, 1.01).
The addition of BMI and comorbidities to the model
further weakened the relationship between CRP and
FMS (AORs for highest vs. lowest CRP quartile = 1.17
(CI 0.96, 1.42) and 1.10 (CI 0.92, 1.32), for BMI and comorbidities, respectively; and, combined OR = 1.07 (CI
0.88, 1.30)) suggesting that these factors may at least
partially explain the observed associations (Table 3). The
inclusion of mood disturbance and sleep impairment,
separately and combined, only slightly attenuated the association of FMS to CRP after adjustment for demographic and lifestyle factors (AOR = 1.01, CI 1.00, 1.01)

Table 3 Model Statistics assessing the association between Fibromyalgia (FMS) and blood serum C-reactive Protein (CRP) quartile
adjusting for BMI and Comorbidity index in a US adult population, 2005–2006 (N = 52,535)
Characteristic

Total

FMS

NonFMS

Models
Odds Ratio (CI) (p-value)
Crudee

Adjusted for
Model
Demographic
1 ± BMIg
and Lifestyle
Factors (Model 1)f

1.02 (1.01–1.02)
(<.0001*)

1.01 (1.00–1.01)
(.004*)

1.01 (1.00–1.01) 1.00 (.997–1.01) 1.00 (.997–1.01)
(.059)
(.267)
(.279)

14,516 (27.6%) 192 (17.1%) 14,324 —
(27.9%)

—

—

Quartile 2b

12,221 (23.3%) 214 (19.0%) 12,007 1.33 (1.09–1.62)
(23.4%) (.004*)

1.13 (0.92–1.38)
(.243)

1.07 (0.88–1.32) 1.04 (0.85–1.28) 1.03 (0.84–1.27)
(.473)
(.686)
(.750)

Quartile 3c

12,755 (24.3%) 297 (26.4%) 12,458 1.78 (1.48–2.14)
(24.2%) (<.0001*)

1.23 (1.02–1.48)
(.032*)

1.12 (0.92–1.37) 1.08 (0.89–1.30) 1.06 (0.87–1.29)
(.244)
(.452)
(.576)

Quartile 4d

13,043 (24.8%) 422 (37.5%) 12,621 2.50 (2.10–2.97)
(24.6%) (<.0001*)

1.35 (1.13–1.62)
(.0009*)

1.17 (0.96–1.42) 1.10 (0.92–1.32) 1.07 (0.88–1.30)
(.120)
(.310)
(.510)

17.48, (<.0001*)

4.02, (.045*)

N (%) / Mean (SD)

CRP level (mg/L) 3.79 (7.22)
CRP Quartile 1a
(ref)

Wald X2, p for
trendt

5.54 (9.77)

3.75
(7.15)

118.42, (<.0001*)

Model 1 ±
comorbiditiesh

—

3.44, (.064)

Model 1 ± BMI
& comorbiditiesr

—

1.23, (.269)

*Significant at p < 0.05
a
C-reactive protein.15–.80 mg/L
b
C-reactive protein.81–1.80 mg/L
c
C-reactive protein 1.81–4.20 mg/L
d
C-reactive protein 4.21–250.6 mg/L
t
Linear trend
e
(R2==.003)
f
Full Model adjusted for demographic covariates Age, Gender, Marital Status, Employment, Education level, White Race, and Household Income; Also adjusted for
lifestyle covariates Tobacco Use and Current Alcohol consumption (R2 = .031)
g 2
(R = .031)
h
Model adjusted for Comorbidity index; index included diabetes, other endocrine disorders (thyroid, Addison’s, and Cushing’s disease), kidney disease, respiratory
conditions (asthma, emphysema, chronic obstructive pulmonary disorder, bronchitis), osteoarthritis, heart disease, liver disease, autoimmune disorders (defined as
having any diagnoses of immune disease, lupus, or rheumatoid arthritis), sleep apnea, irritable bowel syndrome, allergies or frequent sinusitis, or frequent
recurrent headache (R2 = .041)
r 2
(R = .041)
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Table 4 Model Statistics assessing the association between Fibromyalgia (FMS) and blood serum C-reactive Protein (CRP) quartile
adjusting for Sleep impairment and Mood disturbance in a US adult population, 2005–2006 (N = 52,535)
Models
Odds Ratio (CI) (p-value)
Crudee
CRP level (mg/L)

Adjusted for Demographic and Model 1 ± Moodg
Lifestyle Factors (Model 1)f

Model 1 + Mood
& Sleepr

1.01 (1.00–1.01)
(.021*)

1.01 (1.00–1.01)
(.035*)

1.01 (1.00–1.01)
(.031*)

—

—

—

—

1.13 (0.92–1.38) (.243)

1.12 (0.91–1.36) (.287) 1.10 (0.90–1.35) (.357) 1.10 (0.90–1.34) (.363)

1.02 (1.01–1.02) (<.0001*) 1.01 (1.00–1.01) (.004*)

CRP Quartile 1a (ref) —
b

Model 1 ± Sleeph

*

Quartile 2

1.33 (1.09–1.62) (.004 )

Quartile 3c

1.78 (1.48–2.14) (<.0001*) 1.23 (1.02–1.48) (.032*)

d

Quartile 4

Wald X2, p for
trendt

*

*

1.20 (1.00–1.45) (.056) 1.18 (0.98–1.43) (.083) 1.18 (0.97–1.42) (.093)

2.50 (2.10–2.97) (<.0001 ) 1.35 (1.13–1.62) (.0009 )

1.28 (1.07–1.53)
(.007*)

1.26 (1.05–1.51)
(.011*)

1.24 (1.03–1.48)
(.021*)

118.42, (<.0001*)

11.06, (.0009*)

10.40, (.001*)

8.25, (.004*)

17.48, (<.0001*)

*Significant at p < 0.05
a
C-reactive protein .15–.80 mg/L
b
C-reactive protein .81–1.80 mg/L
c
C-reactive protein 1.81–4.20 mg/L
d
C-reactive protein 4.21–250.6 mg/L
t
Linear trend
e 2=
(R =.003)
f
Full Model adjusted for demographic covariates Age, Gender, Marital Status, Employment, Education level, White Race, and Household Income; Also adjusted for
lifestyle covariates Tobacco Use and Current Alcohol consumption (R2 = .031)
g
Mood disturbance derived from responses to four individual questions regarding frequent mood swings, irritability, fatigue and/or inability to
concentrate (R2 = .035)
h
Sleep impairment derived from responses to four individual questions regarding the frequency of short sleep, fitful sleep, insomnia and/or daytime
somnolence (R2 = .037)
r 2
(R = .038)

(Table 4). These findings suggest that any mediating
effect of these factors was modest.
Additional adjustment for statin use, PFOA, and female
reproductive characteristics (menopausal status, age at menarche, and parity) did not appreciably change the relationship between CRP and FMS. Similarly, exclusion of those
with rheumatoid arthritis (n = 1821) and all autoimmune
conditions (n = 2192) did not appreciably affect risk estimates. Likewise, we found no evidence for a modifying effect of age, tobacco use, gender, obesity, menopausal status,
or other factors on the relationship between CRP and FMS.

Discussion
This is the first large, population-based investigation to
examine the relationship between CRP and FMS, to assess the potential influence of BMI and comorbid conditions on this relationship, and to evaluate the potential
mediating role of mood and sleep impairment. In this
cross-sectional study of a large population in the U.S.,
CRP serum level showed a positive association with
FMS, which remained significant after adjustment for
multiple demographic and lifestyle factors, including
age, gender, education level, employment, marital status,
alcohol, and tobacco use. Adjustment for BMI and comorbid conditions substantially attenuated this relationship. These findings are broadly consistent with those
from a recent cross-sectional investigation of 5110 Norwegian men; cases with FMS/Chronic Fatigue Syndrome

(CFS) showed a strong, positive relationship to high
sensitivity-CRP level (FMS/CFS M = 4.79 mg/L; OR for
≥10 mg/L vs. <1 mg/L = 2.6, 95% CI: 1.4, 4.6, p = .002; P
for trend = .006) after adjustment for age, education,
smoking, and cholesterol medication [27]. In contrast, as
stated in the introduction, findings from smaller casecontrol studies examining the association between CRP
and FMS have been inconsistent [24, 26, 28, 30], perhaps
due to varying sample sizes and differing selection criteria among controls; of the four case-control studies
published to date, only one reported significantly higher
CRP levels in FMS patients compared to healthy controls
after adjustment for age, sex, and race [24]. Mean CRP
values found among those with FMS (M = 5.54 mg/L) nor
non-FMS controls (M = 3.75 mg/L) in our study are
nearly within the range for normal CRP values (0.0–
5.0 mg/L) [28] and also within ranges of those found in
most previous studies (mean FMS high-sensitivity CRP
range = 2.6–10.6 mg/L; mean FMS CRP range = 1.0–
4.7 mg/L) [24, 26, 28, 30]. One exception, however, was
that reported by Rus et al. (1.0 ± 0.75) in a Spanish population of women with FMS [28]; in addition to differences
in CRP by BMI status, other possible explanations for the
comparative value found in our study may include gender
variations and/or the influence of FMS comorbidities.
As indicated above, the inclusion of BMI in our model
substantially attenuated the association of FMS to CRP,
suggesting BMI may have largely explained the elevated
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CRP levels in FMS; this was second to the inclusion of
comorbidities. Obesity is a major determinant of elevated CRP in multiple populations [50, 51]. Two studies
to date have considered the potential contribution of
BMI to the profile of CRP in FMS, with one demonstrating a strong and positive correlation [24] while another
demonstrated overweight women with FMS had a higher
mean CRP compared to normal weight women with
FMS (N = 25; M = 3.1 ± 1.4 mg/L and
M = 1.0 ± 0.8 mg/L, respectively). Additionally, in agreement with our study, others have suggested a mediating
effect of BMI on the relation between CRP and FMS;
FMS symptom improvement has followed weight loss
among several FMS cases [52], and a longitudinal study
revealed regular exercise and maintenance of body
weight lowered the risk of FMS [53]. Additionally, one
case-control study found that after adjustment for
demographic factors, BMI was the only significant contributor in a model exploring the relation between CRP
and FMS (r = .062, p < 0.001) [24].
Ours is the first study to assess the contribution of multiple comorbidities on the relation of CRP and FMS. Comorbidities characterized by pain may contribute to the
development of FMS; shared pain mechanisms between
FMS and other conditions with a similar underlying
pathophysiology (e.g., tension headache) or as a comorbidity characterized by inflammation or ongoing peripheral
damage (e.g., autoimmune disorders and osteoarthritis)
and FMS have recently been explored [4, 39, 54]. Our
study found that as the number of comorbidities increased, the odds of FMS increased as well.
Additionally, the presence of sleep impairment and mood
disturbance modestly attenuated, but did not eliminate, the
association between CRP and FMS. No existing studies
have examined the role of sleep impairment on this relationship. We found no evidence supporting mood disorder
as an effect modifier, similar to a study finding where CRP
level did not differ by psychiatric status among those with
FMS [26]. The influence of sleep impairment and mood
disturbance on the relation between CRP and FMS in our
study likely reflects a bidirectional relationship.
The prevalence rate of FMS in our study (2.1%) mirrored recent estimates for the U.S. population [3, 55].
Consistent with previous studies, we found the likelihood of FMS diagnosis was increased in middle-aged females [3, 5]. However, in contrast to findings from two
large studies [3, 56], those who were married or reported
higher levels of education were more likely to report
FMS. Females who had experienced menopause were 1.8
times more likely to have FMS than those who had not;
however, a lack of epidemiological research exists in the
topical area of sex hormones, neurotransmitters, and
FMS. We observed no significant association between
age at menarche or parity and FMS, unlike a German
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case-control study of 653 middle-aged women (FMS
cases = 36) which found, after controlling for age, those
with FMS had significantly later menarche and were less
likely to have ever been pregnant [57].
In agreement with previous cross-sectional and longitudinal studies [3, 53, 58], BMI was strongly and positively related to reported FMS in this large U.S.
population. Additionally, higher BMI has been associated with an increased risk of FMS after adjustment for
mood and/or other health factors [3, 53], including familial FMS diagnosis [58]. Likewise, consistent with findings from a recent cross-sectional study of a nationally
representative sample of U.S. adults (N = 8446, FMS
cases = 201) [3] FMS showed significant positive associations to multiple comorbid conditions in our study after
adjustment for demographic and lifestyle factors; these
included cardiovascular disease, rheumatoid arthritis and
other autoimmune disorders, kidney, respiratory and
liver diseases, and frequent headache. Osteoarthritis was
also associated with a nearly 4-fold likelihood of FMS,
dissimilar from a large, national analysis of U.S. electronic medical records (N = 587,961, FMS cases = 4296)
of only a (unadjusted) 2-fold likelihood [59]. In contrast
to other large studies of U.S. adults [3, 59], diabetes was
not associated with FMS in this sample of adults.
The strengths of this study were its high response rate,
population-based design, and large sample size; this was
the largest comprehensive community study conducted
to date in the Appalachian region of the U.S. We were
able to control for a large number of potential confounders, including comorbid conditions. Misclassification of CRP was unlikely due to standardized assay
procedures used.
This study targeted a population of predominantly
white Appalachian adults in the U.S., potentially limiting
generalizability. Possible misclassification of FMS may
have occurred depending on time the participant was diagnosed and the physician’s awareness and use of the
American College of Rheumatology classification criteria
for FMS diagnosis, first established in 1990. In particular,
poor or incomplete recognition of FMS by healthcare
providers may have led to under-ascertainment [60].
However, such under-ascertainment would be expected
to bias the observed associations toward the null, and
thus would indicate that the magnitudes of relationships
in this study are possibly stronger than those which we
reported. FMS, in addition to most other assessed health
conditions in this cross-sectional survey, was based on
self-report without medical chart review, possibly leading to response or misclassification bias. To our knowledge, no clinical validation study has assessed the
agreement between self-report and medical recordverified data to understand how patients accept and report
their FMS diagnosis, especially in the presence of targeted
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interventions. Additionally, our assessment of the potential relationship between CRP and FMS could be strengthened by inclusion of symptom onset and response to
interventions, for which data was not available.
Unmeasured confounding may have also contributed
to our findings, although our ability to control for a
large number of both known and potential risk factors
for FMS diminishes this possibility. Our study also
lacked specific information on certain conditions previously linked to FMS, including sleep apnea and irritable
bowel syndrome. Although contact with former residents of counties used for study inclusion was
attempted, some may not have participated in the study,
possibly introducing sampling bias. Lastly, we cannot
draw any conclusions regarding causality due to the lack
of a temporal component in our cross-sectional study
design.
In this large cross-sectional study, we observed a significant, positive association between serum CRP and diagnosed FMS, which was largely explained by elevated
BMI and chronic comorbid conditions. Adjustment for
sleep and mood disturbance only modestly attenuated
this association, suggesting that BMI and chronic comorbid conditions may largely account for elevated CRP
levels among FMS patients over the presence of sleep
and mood disturbance. While the clinical utility of CRP
for FMS diagnosis remains elusive at best, the current
work contributes to existing literature by more appropriately assigning responsibility of inflammatory processes
often present in those with FMS to co-occurring chronic
conditions and other factors associated with chronic disease. Further prospective research is needed to determine the relation of CRP and other inflammatory
markers to the development and progression of FMS in
the presence of the potentially complex roles of obesity
and comorbidities.

Conclusion
Findings from this large cross-sectional study indicate the
significant positive cross-sectional association of Fibromyalgia to serum CRP may be explained, in part, by factors such as BMI, comorbidity, impaired mood, and sleep
disturbance. Prospective research is needed to confirm
this, and better clarify the potential mediating influences
on the relationship between Fibromyalgia and CRP.
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